THE WORLD’S FIRST
NON-ORAL
TACROLIMUS MEDICATION SYSTEM
Revolutionizing life-long
Immunosuppression in SOT patients
INTRODUCING NUCLEUS’ BUCCAL TACROLIMUS FILM SYSTEM
TARGETING
CLINICAL TOXICITY AND
PATIENT’S BENEFIT
AFTER SOLID ORGAN TRANSPLANTATION.
THE PROBLEM
Tacrolimus related limitations translating into
therapeutic challenges following oral application
PHYSICOCHEMICAL LIMITATIONS
Poor water solubility
Narrow therapeutic window
PHARMACOKINETIC CHALLENGES
High AUC variations
High intra – and inter-patient blood level fluctuation
Low blood level predictability
Pre-systemic degradation
First-pass effect
Food-effect
THE SOLUTION
The advantage of nucleus’ buccal film application
NUCLEUS’ BUCCAL TACROLIMUS FILM
Direct access to systemic circulation
Increased bioavailability
High Predictability of blood levels
Reduced blood level fluctuations
Significant dose reduction
No pre-systemic degradation:
Drug absorption independent of gastrointestinal motility
No food effect
No first-pass effect
Reduced clinical toxicity
HOW IT WORKS
Once the Nucleus film is secured to the buccal mucosa, Tacrolimus is released over a defined period of time.
The API migrates from the film into the tissue.
Tacrolimus continuously spreads from the tissue into the systemic circulation.